AREDIA
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AREDIA (pamidronate disodium) is a bisphosphonate small-molecule injectable approved in 1991 for treatment of hypercalcemia of malignancy and osteolytic bone metastases in breast cancer and multiple myeloma. It works by inhibiting osteoclast-mediated bone resorption, reducing serum calcium levels and bone destruction. AREDIA is administered intravenously and remains a standard-of-care agent in oncology-supportive care.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30%), the commercial team is likely focused on defending market share and optimizing efficiency rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AREDIA offers limited upside for career growth as a legacy product with approaching LOE and zero linked openings. Roles focus on maintaining market share, managing payer relationships, and ensuring regulatory compliance rather than launching innovation. Professionals should expect stable but not expanding opportunities and may find greater growth potential on Novartis's newer oncology or specialty-care assets.
Brand Manager
Worked on AREDIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.